Details for New Drug Application (NDA): 202158
✉ Email this page to a colleague
NDA 202158 describes RADIOGENIX SYSTEM, which is a drug marketed by Northstar Medical and is included in one NDA. Additional details are available on the RADIOGENIX SYSTEM profile page.
The generic ingredient in RADIOGENIX SYSTEM is technetium tc-99m sodium pertechnetate generator. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m sodium pertechnetate generator profile page.
The generic ingredient in RADIOGENIX SYSTEM is technetium tc-99m sodium pertechnetate generator. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m sodium pertechnetate generator profile page.
Summary for 202158
| Tradename: | RADIOGENIX SYSTEM |
| Applicant: | Northstar Medical |
| Ingredient: | technetium tc-99m sodium pertechnetate generator |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC | Strength | 30-1153mCi/GENERATOR | ||||
| Approval Date: | Feb 8, 2018 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
